Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220131001

Enrollment

225

Registered

2022-01-31

Start date

2019-09-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC patients with unresectable stage IIIB or IV by TNM 7th edition who were treated with platinum-based doublet chemotherapy as first line treatment non small cell lung cancer, prognostic factor, chemotherapy

Interventions

Patients who were responsed in CR/PR by RECIST1.0 ,Patients who were responsed in SD/PD by RECIST1.0

Other,Other

Responders,Non-responders

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. confirmed by cytopathology, 2. treated with platinum plus paclitaxel or platinum plus gemcitabine at least 2 cycles (total 4-6 cycles)

Exclusion criteria

Exclusion criteria: 1. ECOG 3-4, 2. planned for radiotherapy

Design outcomes

Primary

Measure	Time frame
Responder Maximal response after completion of first line chemotherapy RECIST1.0	—

Secondary

Measure	Time frame
Overall survival Cut off date 31 Jan 2020 Death date	—

Countries

Thailand

Contacts

Public ContactChawalit Chayangsu

Suranaree University of Technology

chawalit.sur@cpird.in.th0814941933

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026